BioInvent International AB (BINV) AI Stock Analysis

• Market Cap: kr2.31B
• Dividend Yield: N/A
• Average Volume (3M): 101.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.45
• Revenue Growth: -0.57%
• EPS Growth: -39.92%
• Country: SE
• Employees: 118
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -7.11
• Shares Outstanding: 65,804,360
• 10 Day Avg. Volume: 49,672
• 30 Day Avg. Volume: 101,417
• PEG Ratio: 0.65
• Price to Book (P/B): 1.23
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -36.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: kr34.00 ▼(-3.00%Downside)

BioInvent International AB's overall stock score is primarily impacted by its financial challenges, including declining revenues and negative cash flow, which weigh heavily on the score. Technical indicators show some positive momentum but are not strong enough to offset financial weaknesses. Valuation concerns, highlighted by a negative P/E ratio, further contribute to a low overall score.

BioInvent International AB Business Overview & Revenue Model

Company Description

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.

How the Company Makes Money

BioInvent International AB generates revenue primarily through partnerships and collaborations with other pharmaceutical and biotechnology companies. These collaborations often involve licensing agreements, where BioInvent provides access to its proprietary technology platforms and expertise in antibody discovery and development in exchange for upfront payments, milestone payments, and royalties on future sales of successfully developed drugs. Additionally, the company may receive funding from research grants and government support, as well as potential earnings from its own clinical-stage drug candidates once they reach the market. Key revenue streams include licensing fees, milestone payments, and royalties from strategic partnerships, which are crucial for financing its research and development activities.

BioInvent International AB Financial Statement Overview

Summary

BioInvent International AB faces significant financial challenges, with declining revenues and persistent losses impacting profitability. Despite a strong balance sheet with low debt, the inability to generate positive cash flow from operations is concerning for long-term sustainability.

Income Statement

The company has experienced a severe decline in revenue over the past few years, with TTM (Trailing-Twelve-Months) revenue significantly lower than previous years. Gross profit margins have remained constant at 100%, indicating that all revenue contributes directly to gross profit. However, the net profit margin is deeply negative, reflecting substantial operating losses. The EBIT and EBITDA margins are also negative, highlighting significant operational challenges.

Balance Sheet

The company maintains a strong equity position with an equity ratio of approximately 89% in the TTM period. The debt-to-equity ratio is low, suggesting limited reliance on debt financing. However, the substantial negative net income impacts the return on equity, which remains negative. The company's cash position remains strong, providing some stability amidst operational challenges.

Cash Flow

Operating cash flow has been consistently negative, indicating that the company is not generating enough cash from operations to cover its expenses. Free cash flow has also declined, reflecting increased operational and capital expenditure pressures. Despite these challenges, the company has managed to maintain a positive cash position through financing activities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	60.80M	44.69M	71.46M	326.13M	19.38M	147.37M
Gross Profit	60.80M	44.69M	71.46M	326.13M	19.38M	147.37M
EBITDA	-484.41M	-409.38M	-312.71M	-27.13M	-263.32M	-63.99M
Net Income	-468.06M	-429.38M	-330.30M	-34.09M	-278.96M	-76.67M
Balance Sheet
Total Assets	862.79M	989.24M	1.40B	1.71B	1.45B	802.64M
Cash, Cash Equivalents and Short-Term Investments	742.21M	867.16M	1.07B	1.02B	1.08B	729.27M
Total Debt	15.19M	17.41M	23.24M	26.96M	28.37M	11.60M
Total Liabilities	93.07M	103.42M	90.45M	106.09M	80.32M	59.14M
Stockholders Equity	769.73M	885.82M	1.31B	1.61B	1.37B	743.50M
Cash Flow
Free Cash Flow	-445.08M	-390.50M	-355.00M	-53.60M	-259.10M	-69.32M
Operating Cash Flow	-434.57M	-380.47M	-341.69M	-41.23M	-245.84M	-62.62M
Investing Cash Flow	449.97M	564.35M	59.68M	-628.85M	-467.54M	-6.70M
Financing Cash Flow	-8.62M	-8.46M	23.14M	273.49M	894.87M	644.62M

BioInvent International AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 35.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BINV, the sentiment is Neutral. The current price of 35.05 is below the 20-day moving average (MA) of 36.88, above the 50-day MA of 33.32, and below the 200-day MA of 35.72, indicating a neutral trend. The MACD of 0.57 indicates Positive momentum. The RSI at 48.20 is Neutral, neither overbought nor oversold. The STOCH value of 21.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:BINV.

BioInvent International AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SANION	79 Outperform	kr1.42B	5.39	152.78%	―	1533.99%	―
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	16.99%	1.69%
HNSA	51 Neutral	kr2.28B	―		―	9.53%	41.19%
SYNACT	48 Neutral	€916.47M	―	-48.22%	―	―	67.70%
XSPRAY	47 Neutral	€1.70B	―	-42.24%	―	―	-19.44%
BINV	46 Neutral	kr2.31B	―	-45.80%	―	-0.57%	-39.92%
VICO	45 Neutral	kr1.85B	―	-40.15%	―	―	63.85%

BioInvent International AB Corporate Events

BioInvent’s BI-1808 Shows Promising Results in Phase 2a CTCL Study

BioInvent International AB has announced promising results from its Phase 2a study of BI-1808, a monotherapy for cutaneous T-cell lymphoma (CTCL), showing a 100% disease control rate and significant immune activation. The study, which will be presented at the EHA 2025 congress, highlights the potential of BI-1808 as an immune-modulating therapy with a favorable safety profile, marking a significant milestone in BioInvent’s mission to develop transformative cancer therapies.

BioInvent Reports Positive Phase 1 Results for Cancer Therapy

BioInvent International AB has announced promising results from its Phase 1 study of BI-1206 in combination with KEYTRUDA® (pembrolizumab) for solid tumors, showing significant clinical activity including complete and partial responses. The company plans to initiate Phase 2a expansion cohorts to further investigate this combination in patients with advanced non-small cell lung cancer and uveal melanoma, potentially improving treatment outcomes and addressing unmet medical needs in these cancers.

BioInvent Showcases BI-1910 Development at PAGE 2025

BioInvent International AB announced the presentation of a poster at the PAGE 2025 meeting in Thessaloniki, Greece, highlighting the early clinical development of its anti-TNFR2 drug candidate, BI-1910. The company successfully developed a population model to characterize the pharmacokinetics and pharmacodynamics of BI-1910, which will aid in dose selection for upcoming Phase 2a studies. These studies, planned for the second half of 2025, will evaluate BI-1910 as a single agent and in combination with pembrolizumab for various tumor types. The announcement underscores BioInvent’s progress in cancer immunotherapy and its potential impact on clinical utility and market potential.

BioInvent Sells Mezagitamab Rights to XOMA for $30 Million

BioInvent International AB has sold its future royalty and milestone rights for the cancer drug mezagitamab to XOMA Royalty for up to USD 30 million. This transaction provides BioInvent with non-dilutive capital to advance its drug development programs and reflects XOMA’s increased interest in mezagitamab, enhancing its royalty portfolio with potential future earnings from the drug’s commercial success.

BioInvent Reports Promising Phase 2a Results for BI-1808 in CTCL

BioInvent International AB has announced promising results from its ongoing Phase 2a study of BI-1808, a monotherapy for Cutaneous T-cell Lymphoma (CTCL). The study has shown encouraging clinical activity with one complete response, three partial responses, and four stable diseases among eight evaluable patients. The treatment demonstrated strong immune activation and was well tolerated, with no severe adverse events reported. These findings, to be presented at the EHA 2025 congress, support further development of BI-1808 as a potential novel treatment option for CTCL, reinforced by its recent Fast Track and Orphan Drug Designation by the FDA.

BioInvent Reports Promising Phase 2a Data for NHL Treatment

BioInvent International AB announced promising preliminary data from its ongoing Phase 2a study of a triple combination therapy involving BI-1206, rituximab, and Calquence for treating non-Hodgkin’s lymphoma (NHL). The data showed a 63% objective response rate among the first eight patients, with two complete responses and three partial responses, indicating potential improvements in treatment outcomes and resistance management. The combination therapy has been well tolerated, and BioInvent plans to advance its clinical development, highlighting the potential impact on NHL treatment and the company’s position in cancer immunotherapy.